Dabrafenib and Trametinib in Patients With Non-small Cell Lung Cancer Harboring V600E BRAF Mutation
Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
This is a Phase II, non-randomized, open-label study to assess the efficacy, safety, and
tolerability of dabrafenib and trametinib in stage IV disease to subjects with BRAF V600E
mutant advanced non-small cell lung cancer. Subjects will receive dabrafenib 150 mg bid and
trametinib 2 mg once daily in combination therapy and continue on treatment until disease
progression, death, or unacceptable adverse event.